Get started

Pirs

PIRS Pieris Pharmaceuticals Huge Upside Potential Big pharma working with Pieris Pharmaceuticals, Inc. (PIRS): AZN AstraZeneca 70Mil upfront payment and 5.4Bil potential milestone payments Boston Pharmaceuticals 10Mil upfront payment and 353Mil potential milestone payments Genentech member of RHHBY Roche Group 20Mil upfront payment and 1.4Bil potential milestone payments SGEN Seagen 35Mil upfront payment and 1.2Bil potential milestone payments Servier 40Mil upfront payment and 447Mil potential milestone payments inhaled program PRS-220 for the treatment of IPF. selected to receive a Bavarian government grant of approximately $17 million to evaluate the program for post-COVID pulmonary fibrosis On 8/16/2021 Morgan Stanley reported 1,675,969 shares of PIRS for $6.42Mil, an increase of +104.6% for an ownership of 2.512% in the company On 4/26/2021 HC Wainwright brokerage Reiterated Rating to Buy and a price target of $9.00 On 6/30/2021 Jefferies Financial Group brokerage Boosted Price Target to Buy from $6.00 to $8.00 Usually i have price targets lower than most analysts, but on PIRS, my price target is 10usd. I`m looking forward to read your opinion about it.
PLong
by TopgOptions
4
PIRS Pieris Pharmaceuticals a Sleeping Giant ??PIRS Pieris Pharmaceuticals has collaboration agreements with AstraZeneca, Boston Pharmaceuticals, Servier, Seagen and Genentech, part of Roche. AZN AstraZeneca 70Mil upfront payment and 5.4Bil potential milestone payments Boston Pharmaceuticals 10Mil upfront payment and 353Mil potential milestone payments Genentech member of RHHBY Roche Group 20Mil upfront payment and 1.4Bil potential milestone payments SGEN Seagen 35Mil upfront payment and 1.2Bil potential milestone payments Servier 40Mil upfront payment and 447Mil potential milestone payments So a best case scenario company with 9Bil Revenue PIRS Pieris Pharmaceuticals Market Cap is only 254Mil now!!! On 4/26/2021 HC Wainwright Brokerage set up a price target for PIRS at $9.00 per share. What do you think it`s the real upside potential of Pieris Pharmaceuticals?? PIRS was on my private calls list since 3.42usd.
PLong
by TopgOptions
5
PIRS - To the $4 💰-The company said that it has reached into a multi-program research collaboration and license agreement with Genentech, a member of the Roche Group, to discover, develop and commercialize locally delivered respiratory and ophthalmology therapies that leverage Pieris’ proprietary Anticalin® technology. -PIRS went on to explain that the collaboration will enable it to combine its robust discovery engine with Genentech’s targets, as well as its preclinical and clinical development expertise. As a result, the two will work together to create novel therapies for the treatment of respiratory and other ophthalmological diseases. -Importantly, these two focus areas of the collaboration are uniquely suited to the advantages offered by the small size of Anticalin proteins when delivered locally. -Under the terms of the agreement, Pieris will receive $20 million as an upfront payment and may be eligible to receive more than $1.4 billion in additional milestone payments across multiple programs, as well as tiered royalties for commercialized programs. -In exchange, PIRS will be responsible for the discovery and early preclinical development of the programs. Genentech will be responsible for IND-enabling activities, clinical development, and commercialization of the programs. Moreover, Genentech will have the option to select additional targets in return for an option exercise fee. -This news is huge! First and foremost, entering into a partnership with a company the size of Genentech comes with several advantages. Not to mention, the funding offered through this partnership will help to bolster Pieris Pharmaceuticals’ balance sheet. -At the same time, none of the internal programs at the company are included in the partnership, meaning that everything that comes out of this collaboration will be a new revenue opportunity.
PLong
by caldooninvestment
12
Pieris Pharmaceuticals Inc. NASDAQ: PIRS Shaping-Up Pieris Pharmaceuticals is a clinical-stage biotechnology company that discovers and develops Anticalin-based drugs to target validated disease pathways in a unique and transformative way. The company's clinical pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, inhaled Anticalin proteins to treat respiratory diseases, such as uncontrolled asthma, and a half-life-optimized Anticalin protein to treat anemia. TECHNICAL After breaking-out on large meaningful volume two weeks ago, shares of Pieris Pharmaceuticals Inc. - PIRS now finds itself digesting/consolidating the recent thrust into higher ground on lower volume and in a very constructive manner. When observing the Daily chart above, we can see that PIRS is coming out of a rounding bottom and has recaptured its 200 DMA on the recent move. In addition, we can also see that PIRS now finds itself trading above all of its important moving averages (20/50/200 DMA's), which depicts a favorable technical posture. Both investors/traders may want to continue to monitor the action closely in the days/weeks ahead as we would not be surprised if a move into the $5- $6 zone were to occur in the not too distant future.
P
by InsiderFinancial
bottom of another possible cup and handle Being with this ticker for awhile I've been through the ups and downs. I outlined a few areas where we see run ups and blowoff tops. It's my estimation that we get a 15 10 20% haircut at times with the blowoff. That's the nature of runs maybe? Maybe even more so with spec bio. Anyway I am eyeballing the makings of the bottom of another possible cup and handle formation, we just went through one. PIRS is news driven and has nothing but good news for months. Value based asset that is proving itself, imo.
P
by tradetraderson
Biotech Season Off to a Good Start NASDAQ:PIRS catching some short covering perhaps near end of the day, sending it up near the critical 5 area. Low 4s held very well after a month long run and consolidation. Expecting this to breakout over 5 barring any extraordinary news; not following company details but certainly ripe for a catalyst. Wouldn't be surprised with upgrade ratings or purchase disclosures in the coming weeks that may drive it further in the near-term. Biotech seasonality is upon us, further adding to my long bias here.
PLong
by JustChartThings
1
PIRS on the way to recovery?First close above the EMA10 in 20 trading days, when stocks began tumbling in January. In at 1.57 last week, looking for a continuation closing above the EMA10 on Monday. Recent MACD cross and OBV increase support the continuation; RSI cross above 50 and we may see a return to the MA50 in the near term. PIRS seems like a good long-term value play here, but taking profits at appropriate times seems like the best thing to do in the current market unless you have a lot of flexibility.
PLong
by JustChartThings
Time to go long on PIRS, very long.The has been absolutely no fundamental change to this bio company that has multiple big pharma partners. Yet due to the overall biotech downturn NASDAQ:PIRS was hit pretty hard. This presents a true 10 bagger opportunity , and Im not even remotely stretching the truth. The technicals show you why right now is the PERFECT time to buy. A little due diligence will show you why its a must hold in 2016. As you will find here --> there is plenty in the pipeline, both propietary and partnered. And when your partners are this strong, its hard to fail.
PLong
by WholeLottaBull